A Win For Sonnet BioTherapeutics Holdings, Inc.
Fri, Sep 12, 2025 at 07:30 PM
Sonnet BioTherapeutics Holdings, Inc. (SONN:NASDAQ) jumped higher at $5.9, a gain of 49%. On Fri, Sep 12, 2025, SONN:NASDAQ touched a New 2-Week High of $5.9. The stock appeared on our News Catalysts scanner on Sat, Aug 30, 2025 at 10:01 PM in the 'SPLIT' category. From Fri, Aug 29, 2025, the stock recorded 44.44% Up Days and 40.00% Green Days
The stock spiked on Mon, Jul 14, 2025 at $19.3 with a volume of 44M+.
About Sonnet BioTherapeutics Holdings, Inc. (SONN:NASDAQ)
Sonnet BioTherapeutics Holdings Inc is a biotechnology company engaged in the development of biologic drugs focused on human antibody binding technology. The firm's pipeline products include SON-080 (low-dose IL-6), SON-081 (low dose IL-6), SON-1010 (IL12-FHAB), and others.
Top 10 Gainers:
- GlucoTrack, Inc. (GCTK:NASDAQ), 117.45%
- HCW Biologics Inc. (HCWB:NASDAQ), 68.37%
- Vestand Inc Cl A (New) (VSTD:NASDAQ), 65.12%
- Allied Gaming & Entertainment Inc. (AGAE:NASDAQ), 62.44%
- Sonnet BioTherapeutics Holdings, Inc. (SONN:NASDAQ), 48.99%
- Envirotech Vehicles, Inc. (EVTV:NASDAQ), 48.91%
- Huize Holding Limited (HUIZ:NASDAQ), 48.76%
- iSpecimen Inc. (ISPC:NASDAQ), 47.73%
- Zenta Group Company Limited (ZGM:NASDAQ), 47.65%
- Entero Therapeutics, Inc. (ENTO:NASDAQ), 36.96%